ILMN240705C110000
- 0.10
- -0.30-75.00%
Illumina Newsroom
Illumina Is Maintained at Outperform by RBC Capital
Illumina Is Maintained at Outperform by RBC Capital
A Glimpse Into The Expert Outlook On Illumina Through 10 Analysts
In the preceding three months, 10 analysts have released ratings for Illumina (NASDAQ:ILMN), presenting a wide array of perspectives from bullish to bearish.The following table summarizes their recent
RBC Capital Maintains Outperform on Illumina, Lowers Price Target to $242
RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:ILMN) with a Outperform and lowers the price target from $249 to $242.
Illumina Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 132.07% RBC Capital $249 → $242 Maintains Outperform 06/11/2024 67.82% Evercore ISI Group $195
RBC Capital Maintains Illumina(ILMN.US) With Buy Rating, Cuts Target Price to $242
RBC Capital analyst Conor McNamara maintains $Illumina(ILMN.US)$ with a buy rating, and adjusts the target price from $249 to $242.According to TipRanks data, the analyst has a success rate of 20.7% a
Express News | Illumina Inc : RBC Cuts Target Price to $242 From $249
Illumina to Record $1.47 Goodwill Impairment Charge in Q2 After Grail Spin-Off
Illumina (ILMN) said Thursday it estimates a goodwill impairment charge of $1.47 billion in Q2, in relation to the recent spin-off of cancer diagnostic test maker Grail (GRAL). Illumina also expects a
Barclays Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $100
Barclays analyst Luke Sergott maintains $Illumina(ILMN.US)$ with a sell rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 40.5% and a total a
illumina will record a goodwill impairment expense of $1.47 billion related to Grail in Q2.
On June 28th, Glon Hui. The gene testing company illumina in the United States stated that it will incur goodwill impairment expenses of US $1.47 billion in the second quarter, which is related to the recently divested cancer diagnostic test manufacturer Grail, and may incur additional impairment expenses of about US $420 million for Grail's ongoing research and development intangible assets (IPR&D) recognition. However, the company added that there are no significant cash expenditures expected in the future related to these impairments. In December last year, activist investor Carl Icahn said that Grail's higher-than-expected spending and delayed testing progress also forced
Express News | Illumina Inc - Charge as a Result of Impairment Test Performed by Co for Goodwill and Non-Amortizing in-Process Research and Development
Express News | Illumina Inc - Estimates That It Will Recognize an Impairment Charge for Grail Ipr&D Intangible Asset in Q2 of 2024 Equal to $420 Mln
Express News | Illumina Inc - Does Not Expect Any Material Future Cash Expenditures Related to Impairments
Express News | Illumina Inc - Estimates That It Will Recognize a Goodwill Impairment Charge in the Second Quarter of 2024 Equal to $1,466 Million
Baird Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $119
Baird analyst Catherine Ramsey Schulte maintains $Illumina(ILMN.US)$ with a hold rating, and adjusts the target price from $128 to $119.According to TipRanks data, the analyst has a success rate of 52
Cancer detection product supplier Grail (GRAL.US) will debut on Nasdaq tonight, having split from Illumina (ILMN.US).
Grail, a cancer detection product supplier split off from life science company Illumina, went public on Nasdaq on Tuesday.
Grail to Begin Trading as Illumina Completes Spinoff
Once Valued At Around $7B, Cancer Blood Test Developer Grail To Kickstart Trading On NASDAQ
Nearly four years after first pitching for Grail Inc. (NASDAQ:GRAL), Illumina Inc. (NASDAQ:ILMN) announced Monday that it would spin off the cancer blood test developer. In July 2021, Illumina said it
Illumina Completes Grail Spin-Off Into Publicly Traded Entity, Holds Minority Stake
Illumina (ILMN) late Monday said it has successfully spun off its former Grail cancer diagnostics unit into a stand-alone public company that will trade under the ticker GRAL starting Tuesday. As part
Illumina Finishes Spinning Off Cancer-Test Maker Grail -- WSJ
By Peter Loftus Grail is back to being an independent company after a tumultuous few years, and its CEO says its making progress toward broader use of its cancer-detection blood test. Illumina, the
GRAIL Will Be Listed And Commence Regular-Way Trading On The Nasdaq Under The Symbol "GRAL" As Of June 25, 2024.
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25GRAIL is Building and Scaling a Groundbreaking New Cancer Screening TechnologyGRAIL, Inc. (NASDAQ:GRAL, formerly GRAIL, LLC